Anixa Biosciences logo
Anixa Biosciences
ANIX | NASDAQ
Chart Builder DCF Calculator
$2.55
-$0.07 (-2.67%)
At close: Nov 16, 2026, 4:00 PM ET
$2.65
+$0.10 (+4.12%)
After-hours: Nov 16, 2026, 7:53 PM ET

Anixa Biosciences Company Profile

Company profile explained

Company Profile

Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.

Key Executives

Name Position
Amit Kumar Chief Executive Officer, Chairman & Co-Chair of CBAB
Michael J. Catelani President, Chief Operating Officer, Chief Financial Officer & Corporate Secretary
Pamela D. Garzone Chief Development Officer & Chair Breast Cancer Clinical Advisory Board

Latest SEC Filings

Date Type Title
Oct 26, 2026 4 Filing
Oct 22, 2026 4 Filing
Sep 30, 2026 4 Filing
Sep 28, 2026 4 Filing
Sep 28, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 14, 2026 4 Filing
Sep 14, 2026 4 Filing
Sep 11, 2026 4 Filing
Sep 09, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Anixa Biosciences
Anixa Biosciences logo
Country United States
IPO Date Oct 7, 1983
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Amit Kumar

Contact Details

3150 Almaden Expressway San Jose, California 95118 United States

Stock Details

Ticker Symbol ANIX
Exchange NASDAQ
Fiscal Year November - October
Reporting Currency USD
CIK Code 0000715446
CUSIP Number 03528H109
ISIN Number US03528H1095
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.